Mounjaro for Heart Failure: Off-Label Use, Evidence, and Monitoring

What Mounjaro Is Approved For (and What It Is Not)

Tirzepatide, marketed as Mounjaro, received FDA approval in May 2022 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [1]. A higher-dose formulation (Zepbound) later received approval for chronic weight management. Neither formulation carries an FDA indication for heart failure of any type.

Using Mounjaro to treat heart failure is off-label prescribing. Off-label does not mean unsupported. It means the prescriber is relying on published evidence and clinical judgment rather than a label-specified indication. The American College of Cardiology and the Heart Failure Society of America have both acknowledged GLP-1 receptor agonist data in obesity-related HFpEF, though formal guideline integration for tirzepatide specifically is still pending [2]. Physicians who prescribe tirzepatide for cardiac indications accept responsibility for informed consent, outcome tracking, and a monitoring protocol that accounts for the drug's metabolic and cardiovascular effects.

The SUMMIT Trial: What the Data Actually Show

The SUMMIT trial (N=731) randomized patients with HFpEF (ejection fraction ≥50%) and a BMI of 30 or higher to tirzepatide (up to 15 mg weekly) or placebo for 52 weeks [3]. The primary endpoint was a hierarchical composite of cardiovascular death, heart failure events, change in 6-minute walk distance, and Kansas City Cardiomyopathy Questionnaire score.

Tirzepatide won on every layer of that composite. The win ratio was 1.65 (95% CI 1.37 to 1.99, P<0.001). Heart failure hospitalizations and urgent visits dropped by 38%. The 6-minute walk distance improved by a mean of 18.3 meters more than placebo. KCCQ clinical summary scores rose by 6.9 points beyond the placebo group, crossing the 5-point threshold considered clinically meaningful [3].

These are not marginal signals. A 38% reduction in worsening heart failure events from a single agent, in a syndrome with limited pharmacologic options, places tirzepatide among the most promising HFpEF interventions tested to date. For comparison, empagliflozin in EMPEROR-Preserved (N=5,988) showed a 21% reduction in the composite of cardiovascular death or heart failure hospitalization [4]. The populations differ, and cross-trial comparisons have known limitations, but the magnitude of the SUMMIT effect is notable.

Weight loss likely drives a large share of the benefit. SUMMIT participants lost a mean of 13.9% of body weight at 52 weeks, compared with 2.2% for placebo [3]. Obesity increases left ventricular filling pressure, promotes systemic inflammation, and expands plasma volume. Reducing visceral and epicardial fat reverses several of these pathways simultaneously.

Why Off-Label Cardiac Prescribing Requires a Monitoring Protocol

The SUMMIT data are encouraging, but a single Phase III trial is not the same as a fully validated indication. The FDA approval process requires replicated efficacy, long-term safety data, and manufacturing consistency specific to the proposed use. None of that exists yet for tirzepatide in heart failure.

That gap creates specific risks. Heart failure patients take multiple medications with overlapping hemodynamic effects. Diuretic requirements can shift as body weight drops. Renal function may fluctuate. GI side effects (nausea, vomiting, diarrhea) can cause dehydration that destabilizes a patient already on loop diuretics and SGLT2 inhibitors. Without systematic monitoring, a well-intentioned prescription becomes a source of preventable harm.

Dr. Milton Packer, a cardiologist at Baylor University Medical Center who has published extensively on HFpEF, has stated: "The obesity phenotype of HFpEF is a real entity, and weight loss is a real treatment, but clinicians need to monitor these patients as carefully as they would with any new heart failure therapy" [5].

Baseline Assessments Before Starting Tirzepatide Off-Label

Before initiating tirzepatide for a cardiac indication, a structured baseline evaluation reduces downstream complications. The following assessments align with general heart failure management standards from the ACC/AHA/HFSA 2022 guidelines [2] and pharmacovigilance principles for GLP-1 class agents [6].

Cardiac biomarkers. NT-proBNP (or BNP) at baseline gives a reference point. In SUMMIT, tirzepatide reduced NT-proBNP by 30.8% more than placebo at 52 weeks [3]. Without a starting value, that trajectory is invisible.

Echocardiography. Confirm the HFpEF diagnosis. Ejection fraction must be ≥50%, and diastolic dysfunction markers (E/e' ratio, left atrial volume index) should be documented. Misclassifying a patient with reduced ejection fraction could lead to inappropriate therapy choices.

Renal panel. Serum creatinine, eGFR, and electrolytes. GLP-1 receptor agonists have shown renal protective effects in some populations [7], but dehydration from GI side effects can acutely worsen kidney function in patients already on diuretics or ACE inhibitors.

Body composition metrics. Weight, BMI, and waist circumference. The SUMMIT trial enrolled patients with BMI ≥30. Prescribing tirzepatide off-label for HFpEF in patients below that threshold lacks even preliminary evidence.

Medication reconciliation. Document all diuretics, SGLT2 inhibitors, antihypertensives, and insulin. Tirzepatide lowers blood glucose and may reduce insulin requirements by 40% to 60% in patients with concurrent diabetes [1]. Hypoglycemia risk rises if insulin doses are not proactively adjusted.

GI history. Gastroparesis, severe GERD, or a history of pancreatitis may be relative contraindications. The FDA label for Mounjaro warns against use in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome [1].

The Monitoring Schedule: Titration Phase

Tirzepatide follows a fixed-dose escalation: 2.5 mg for 4 weeks, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg, each step lasting at least 4 weeks [1]. During titration, monitoring should occur at each dose increase. That means clinic contact (in-person or telehealth) every 4 weeks for approximately 20 to 24 weeks.

At every titration visit, assess:

• Body weight and vital signs (blood pressure, heart rate, orthostatic check)
• Symptom review: dyspnea, edema, exercise tolerance, GI side effects
• Serum creatinine and electrolytes (potassium, sodium, magnesium)
• Volume status: jugular venous pressure, peripheral edema, daily weight trend
• Medication adjustments needed (diuretic dose, insulin dose, antihypertensive dose)

Heart rate deserves specific attention. GLP-1 receptor agonists increase resting heart rate by 2 to 4 bpm on average [8]. In the SUSTAIN-6 trial of semaglutide, the mean increase was 2.5 bpm [9]. For most patients, this is clinically insignificant. For a patient with heart failure on a beta-blocker titrated to a specific rate target, even small increases may prompt reassessment. If resting heart rate rises above 80 to 85 bpm consistently, evaluate beta-blocker dosing and volume status before attributing the change to tirzepatide alone.

GI side effects peak during titration. In the SURPASS-1 trial, nausea occurred in 12% to 18% of tirzepatide-treated patients and was most common in the first 4 to 8 weeks [10]. Vomiting and diarrhea can cause rapid fluid loss. In a patient on furosemide 40 mg daily, even 24 hours of significant vomiting can precipitate prerenal azotemia and dangerous electrolyte shifts. Instruct patients to hold diuretics during acute GI illness and contact their care team within the same day.

Maintenance-Phase Monitoring

Once the target dose is reached and tolerated for at least 4 weeks, monitoring intervals can extend to every 8 to 12 weeks. This is not a signal to reduce vigilance. It reflects stabilization, not resolution of risk.

Every 8 to 12 weeks:

• Weight, blood pressure, heart rate
• Symptom assessment (NYHA class, KCCQ if using structured tools)
• Basic metabolic panel including eGFR
• NT-proBNP (quarterly is reasonable; more frequent if symptoms change)
• HbA1c every 3 months if the patient has concurrent diabetes

Every 6 months:

• Echocardiography to reassess diastolic parameters and ejection fraction
• Review of overall medication burden: has weight loss allowed diuretic reduction? Has blood pressure dropped enough to taper antihypertensives?

Annually:

• Comprehensive reassessment of the off-label rationale. Is the patient still benefiting? Has new evidence changed the risk-benefit calculus? The 2022 ACC/AHA/HFSA guidelines recommend periodic reassessment of all heart failure therapies [2].

Dr. Mikhail Kosiborod, lead investigator of the SUMMIT trial and professor at the University of Missouri-Kansas City, noted: "We saw sustained improvements in heart failure symptoms, physical limitations, and biomarkers over 52 weeks, but long-term outcomes beyond one year still need dedicated study" [3].

Diuretic Adjustments During Weight Loss

This is the highest-risk practical issue. A patient who loses 10% to 15% of body weight over 6 to 12 months will almost certainly need diuretic dose reduction. Plasma volume contracts as adipose tissue shrinks. Continuing the same furosemide dose in a patient who has lost 15 kg creates a setup for hypotension, acute kidney injury, and electrolyte derangements.

The STEP-HFpEF trial of semaglutide 2.4 mg (N=529) demonstrated this dynamic clearly. Patients lost a mean of 13.3% body weight, and diuretic requirements fell in a meaningful proportion of participants [11]. SUMMIT did not publish granular diuretic adjustment data, but the magnitude of weight loss (13.9%) makes the same hemodynamic logic apply.

A practical threshold: for every 5% of body weight lost, reassess loop diuretic dosing. If the patient is euvolemic (no edema, no orthopnea, stable daily weights), consider reducing furosemide by 25% to 50%. Document the rationale. Recheck creatinine and electrolytes within 1 to 2 weeks of any diuretic change.

When to Pause or Discontinue Tirzepatide

Not every patient will tolerate the drug, and not every patient will benefit. Clear stopping rules prevent therapeutic inertia.

Pause tirzepatide if:

• Persistent vomiting or diarrhea lasting more than 48 hours despite antiemetics
• Acute kidney injury (creatinine rise ≥0.3 mg/dL or ≥1.5x baseline within 7 days)
• Symptomatic hypotension (systolic BP consistently below 90 mmHg)
• Suspected pancreatitis (severe epigastric pain with lipase elevation above 3x upper limit of normal)

Discontinue tirzepatide if:

• Weight loss plateau with no cardiac benefit after 6 months at maximum tolerated dose
• Worsening heart failure (new hospitalization, rising NT-proBNP trend, declining 6-minute walk distance) despite adequate dosing
• Development of a contraindication (e.g., new diagnosis of medullary thyroid carcinoma or MEN2)
• Patient preference after informed discussion

The decision to stop should be as deliberate as the decision to start. Document the clinical reasoning in the same structured format used at initiation.

GLP-1 Class Cardiovascular Evidence Beyond SUMMIT

Tirzepatide does not exist in a vacuum. The broader GLP-1 receptor agonist class has accumulated substantial cardiovascular outcome trial data that informs, though does not directly justify, its off-label cardiac use.

Liraglutide in LEADER (N=9,340) reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 13% (HR 0.87, 95% CI 0.78 to 0.97) [12]. Semaglutide in SELECT (N=17,604) reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.72 to 0.90) in patients with overweight/obesity without diabetes [13]. The STEP-HFpEF and STEP-HFpEF DM trials of semaglutide showed improvements in symptoms, physical limitations, and exercise function in HFpEF patients with obesity [11].

Tirzepatide's dual GIP/GLP-1 mechanism distinguishes it from pure GLP-1 agonists. Whether GIP receptor activation adds cardiac benefit or introduces unique risks remains an open question. The SURPASS-CVOT (now published) evaluated tirzepatide's cardiovascular safety in type 2 diabetes and confirmed noninferiority to placebo for major adverse cardiovascular events [14]. Superiority for heart failure endpoints was not a prespecified analysis in that trial.

Insurance, Cost, and Access Barriers

Off-label prescribing introduces a coverage problem. Most commercial insurers and Medicare Part D plans cover Mounjaro for type 2 diabetes, often with prior authorization. Coverage for heart failure without a diabetes diagnosis is inconsistent at best and denied at most plans.

The list price for Mounjaro is approximately $1,023 per month [1]. Zepbound (the obesity-indication formulation of tirzepatide) carries a similar price. The Eli Lilly savings card may reduce cost for commercially insured patients, but it excludes government insurance. Patients should be counseled about out-of-pocket cost before starting off-label therapy. Prescribers should document the clinical rationale in detail, referencing published trial data, to support prior authorization appeals.